Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Autolus Therapeutics plc (AUTL)

1.82   -0.05 (-2.67%) 03-24 16:00
Open: 1.84 Pre. Close: 1.87
High: 1.85 Low: 1.74
Volume: 295,563 Market Cap: 315(M)

Technical analysis

as of: 2023-03-24 4:24:11 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 2.32     One year: 2.51
Support: Support1: 1.74    Support2: 1.44
Resistance: Resistance1: 1.99    Resistance2: 2.15
Pivot: 1.99
Moving Average: MA(5): 1.93     MA(20): 1.96
MA(100): 2.1     MA(250): 2.64
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 20.1     %D(3): 38
RSI: RSI(14): 40.1
52-week: High: 4.73  Low: 1.6
Average Vol(K): 3-Month: 564 (K)  10-Days: 482 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ AUTL ] has closed above bottom band by 6.8%. Bollinger Bands are 49.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 57 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.85 - 1.86 1.86 - 1.87
Low: 1.72 - 1.73 1.73 - 1.74
Close: 1.8 - 1.82 1.82 - 1.84

Company Description

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.

Headline News

Sat, 18 Mar 2023
Bryan, Garnier & Co Begins Coverage on Autolus Therapeutics ... - MarketBeat

Mon, 13 Mar 2023
Analysts Offer Predictions for Autolus Therapeutics plc's Q1 2023 ... - MarketBeat

Wed, 08 Mar 2023
Tesla To Rally More Than 12%? Here Are 10 Other Analyst ... - Benzinga

Wed, 08 Mar 2023
Autolus Therapeutics plc (NASDAQ:AUTL) Q4 2022 Earnings Call Transcript - Yahoo Finance

Wed, 01 Mar 2023
11 High Growth UK Stocks to Buy - Yahoo Finance

Tue, 14 Feb 2023
Autolus Therapeutics: The Story Has Improved (NASDAQ:AUTL) - Seeking Alpha

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. -91 (M)
Shares Float 0 (M)
% Held by Insiders 1.7308e+008 (%)
% Held by Institutions 5.705e+007 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -811000
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -1.62
Profit Margin (%) 0
Operating Margin (%) -2
Return on Assets (ttm) 634.1
Return on Equity (ttm) -23.4
Qtrly Rev. Growth 6.36e+006
Gross Profit (p.s.) 572.02
Sales Per Share -51.01
EBITDA (p.s.) -8.38354e+007
Qtrly Earnings Growth -1.6017e+008
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value -1.14
Price to Sales -0.04
Price to Cash Flow 0

Stock Dividends

Dividend 1.13e+006
Forward Dividend 877410
Dividend Yield 62087900%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.